Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 2/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3568940 | 0.86 | HDAC3 (0.44) | KMT2AALDH1A1HTR2AMAPTTSHR | |
| SCHEMBL28630917 | 0.85 | PDCD1 (0.48) | PDCD1CD274KMT2AALDH1A1MAPT | |
| SCHEMBL5877 | 0.84 | HTR2C (0.41) | PDCD1CD274HTR2CFYNPDGFRB | |
| SCHEMBL18894529 | 0.78 | SLC6A2 (0.49) | KMT2AALDH1A1 | |
| SCHEMBL17239836 | 0.75 | NFE2L2 (0.58) | HTR2CFYNPDGFRBPDGFRAKMT2A | |
| SCHEMBL9862162 | 0.74 | MAOB (0.53) | HTR2CKMT2AMAPTCYP3A4 | |
| SCHEMBL12341798 | 0.74 | ACHE (0.52) | PDCD1CD274KMT2AALDH1A1MAPT | |
| SCHEMBL48353 | 0.74 | APLNR (0.59) | HTR2CKMT2AALDH1A1HTR2AMAPT | |
| SCHEMBL29148400 | 0.73 | PDGFRB (0.47) | CD274HTR2CFYNPDGFRBPDGFRA | |
| SCHEMBL5802 | 0.73 | FFAR4 (0.45) | ABCB1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8853258-B2 | C-linked hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853258-B2 | C-linked hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853258-B2 | C-linked hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2488489-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | BROWN MATTHEW FRANK (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | BROWN MATTHEW FRANK (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | BROWN MATTHEW FRANK (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011045703-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011045703-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | HAX1, LPXN, AGXT | PDCD1 2406/4885CD274 2069/4885HTR2C 4393/4885 |
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LCT, AGXT, PRXL2A | PDCD1 2329/4885CD274 2559/4885HTR2C 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.